India has recorded more than 63 Lakh Covid-19 Vaccine jabs in the last 24 hours. With this India’s cumulative Covid-19 vaccination coverage crosses 35 Crore. According to the CoWin portal, a total of 28.35 crore people have been given the first dose of the vaccine and a total of 6.25 crore people have received their second dose.
A study conducted by ICMR shows that an infection-preventing vaccine with 60% efficacy covering all priority groups would reduce peak symptomatic incidence of Covid-19 by 20.6% and total deaths by 29.7%. The study supports an approach of targeted vaccination to vulnerable or priority group that seeks to reduce the incidence of mortality and offer greater protection against the disease. The study also stated that COVID-19 recovered individuals with one or two doses of vaccine have relatively higher protection against Delta variant in comparison to those administered either one or two doses of Covishield.
According to reports, the Covid-19 vaccine developed by Novavax may get approval for use in India between July and September. Novavax Chief Executive Officer has said that it is likely to have a higher price than Serum Institute of India’s Covishield.
A report named ‘Responsive and Agile Vaccination Strategies Against COVID-19 in India, published by Lancet Global Health has said that flexible and agile vaccination strategies can play a vital role in protecting lives in India. It said the experience from influenza pandemics in 1918 and 2009, as well as the current COVID-19 pandemic in other countries, highlight the potential for not just two, but subsequent waves of infection.
In June, Pfizer CEO Albert Bourla had said that his firm was in the final stages of getting approval for its Covid-19 vaccine from the Indian government, adding that when approved, the pharma giant will supply one billion doses to India within this year.